Hematology
What they do most for Medicare patients
| Service, sort | Times billed, sort |
|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 131,318 |
| Flow cytometry technique for dna or cell analysis, each additional marker | 85,667 |
| Established patient office or other outpatient visit, 40-54 minutes | 81,888 |
| Detection test by nucleic acid for organism, amplified probe technique | 81,879 |
| Special stained specimen slides to examine tissue, each additional procedure | 80,329 |
| Pathology examination of tissue using a microscope, intermediate complexity | 65,392 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 63,638 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 59,179 |
| Insertion of needle into vein for collection of blood sample | 39,366 |
| Blood test, comprehensive group of blood chemicals | 38,174 |
| Established patient office or other outpatient visit, 20-29 minutes | 35,364 |
| Detection test for candida species (yeast), amplified probe technique | 32,718 |
| Special stained specimen slides to examine tissue including interpretation and report | 30,840 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 27,078 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 24,294 |
| Protein measurement, serum | 23,591 |
| Special stained specimen slides to examine tissue, initial procedure | 23,337 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 18,577 |
| Immunologic analysis technique on serum (immunofixation) | 17,263 |
| Preparation of tissue for examination by removing any calcium present | 17,124 |
| Lactate dehydrogenase (enzyme) level | 16,917 |
| Cell examination of specimen, concentration technique | 15,569 |
| Bone marrow, smear interpretation | 15,300 |
| New patient office or other outpatient visit, 60-74 minutes | 14,204 |
| Microscopic genetic analysis of tumor, manual | 11,583 |
| Injection of drug or substance under skin or into muscle | 11,195 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 9,928 |
| Administration of chemotherapy into vein, 1 hour or less | 8,937 |
| Injection of additional new drug or substance into vein | 8,935 |
| Cell examination of urine, manual | 8,829 |
| Molecular pathology procedure; physician interpretation and report | 8,710 |
| Magnesium level | 7,854 |
| Uric acid level, blood | 6,659 |
| Blood smear interpretation by physician with written report | 6,615 |
| Ferritin (blood protein) level | 6,495 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 6,367 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 6,354 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 6,353 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 6,347 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 6,347 |
| New patient office or other outpatient visit, 45-59 minutes | 6,294 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 6,192 |
| Phosphate level | 5,930 |
| Iron level | 5,924 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 5,846 |
| Iron binding capacity | 5,811 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 5,696 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 5,667 |
| Protein measurement, body fluid | 5,461 |
| Pathology examination of tissue using a microscope, moderately high complexity | 5,117 |
| Immunologic analysis technique on body fluid, other fluids with concentration | 4,464 |
| Microscopic genetic analysis of tissue, computer-assisted technology, initial procedure, each multiplex procedure | 4,228 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 4,058 |
| Flow cytometry technique for dna or cell analysis, first marker | 3,779 |
| Interpretation and report of genetic testing | 3,462 |
| Coagulation function screening test with interpretation and report | 3,389 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 3,361 |
| Gammaglobulin (immune system protein) measurement | 3,338 |
| Genetic sequencing localization, initial procedure | 2,955 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 2,895 |
| Hospital discharge day management, more than 30 minutes | 2,823 |
| Cell examination of specimen, selective cellular enhancement technique | 2,784 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 2,614 |
| Psa (prostate specific antigen) measurement, total | 2,585 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 2,505 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 2,422 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2,380 |
| Administration of additional new drug or substance into vein, 1 hour or less | 2,368 |
| Pathology examination of tissue using a microscope, moderately low complexity | 2,362 |
| Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 2,344 |
| Cyanocobalamin (vitamin b-12) level | 2,095 |
| Administration of chemotherapy into vein, each additional hour | 1,959 |
| Testosterone (hormone) level, total | 1,830 |
| Pathology clinical consultation for clinical problem, 5-20 minutes | 1,775 |
| Pap test, automated thin layer preparation; automated system | 1,769 |
| Genetic sequencing localization, each additional procedure | 1,759 |
| Telephone medical discussion with physician, 21-30 minutes | 1,757 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 1,677 |
| Microscopic genetic analysis of tissue, manual, each additional procedure | 1,629 |
| Carcinoembryonic antigen (cea) protein level | 1,484 |
| Established patient office or other outpatient visit, 10-19 minutes | 1,429 |
| Detection test by nucleic acid for human papillomavirus (hpv), high-risk types | 1,425 |
| Hospital discharge day management, 30 minutes or less | 1,403 |
| Telephone medical discussion with physician, 11-20 minutes | 1,388 |
| Evaluation of fine needle aspirate with interpretation and report | 1,382 |
| Measurement of immunoglobulin light chains | 1,372 |
| Blood test, thyroid stimulating hormone (tsh) | 1,349 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 1,281 |
| Vitamin d-3 level | 1,264 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 1,245 |
| Antibody identification test, platelet associated immunoglobulin assay | 1,237 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 1,168 |
| Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique | 1,149 |
| Infusion into a vein for hydration, each additional hour | 1,129 |
| Ct guidance for insertion of radiation therapy fields | 1,125 |
| Infusion into a vein for hydration, 31-60 minutes | 1,101 |
| New patient office or other outpatient visit, 30-44 minutes | 1,066 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 1,063 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 1,031 |
| Special stained specimen slides to identify organisms including interpretation and report | 1,018 |
Sources: Medicare Care Compare (hospitals and schools; Medicare-enrolled clinicians), CMS Medicare Physician & Other Practitioners 2023 (services), Medicare Part D Prescribers 2024 (drugs).